The E-Town Biomedical Park-backed biopharmaceutical company, which has some 15 assets in clinical trials, has completed a two-tranche series C round.
China-based pharmaceutical product developer Beijing Mabworks Biotech has closed RMB1.13bn ($160m) in series C funding from investors including industrial park Beijing E-Town Biomedical Park, DealStreetAsia reported yesterday.
The round was made up of two tranches co-led by investment bank China International Capital Corporation’s CICC Qide Innovative Biopharmaceutical Equity Investment Fund, investment bank Citic Securities, Lyzz Capital and Huge Capital.
Beijing E-Town’s International Investment & Development unit also took part in the round, as did Bocom International, a subsidiary of financial…
